Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 71
Selected: 0
NCT IDTitle
NCT04518046Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies
NCT04685135Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
NCT06875310A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT05840510Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)
NCT02993991Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity
NCT05542342Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.
NCT02236195Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
NCT00511576Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors
NCT05634525Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients
NCT03680521Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma
NCT04793958Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
NCT05472623Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab
NCT03785249Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
NCT04975256Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)
NCT04299113Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma
NCT00374296MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease
NCT02018926Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
NCT05578092A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway
NCT01930006Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State
NCT00697632Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies
NCT00679133Safety Study of Oral MGCD265 Administered With Interruption to Subjects With Advanced Malignancies
NCT04925986Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC
NCT02978859Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas
NCT05178888Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)
NCT00431873A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia
NCT04935112A Study to Explore the Effect of Acid-reducing Agents
NCT05737706Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
NCT04772612A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib
NCT04418661Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies
NCT05848843A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations
NCT06248606Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
NCT00324194A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes
NCT00372437A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine
NCT03906071Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
NCT05609578Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
NCT02805660Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC
NCT04613596Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
NCT05924152A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib
NCT03606174A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
NCT02117245Single Dose Comparative Bioavailability Study Of MGCD265 In Healthy Male And Female Volunteers
NCT02664935National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
NCT06130254Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
NCT03220477Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.
NCT00359086Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma
NCT03575598Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study
NCT04800614A Study to Explore the Effect of Food Before a Single Dose of Sitravatinib
NCT05263986The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid Tumors
NCT04887870Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study
NCT04123704Sitravatinib in Metastatic Breast Cancer
NCT00358982Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma